Zevra Therapeutics, Inc. Long-term Line of Credit, Noncurrent
Zevra Therapeutics, Inc. (ZVRA) had Long-term Line of Credit, Noncurrent of $37.94 million as of 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermLineOfCredit · last filed 2024-05-09
- 2024-03-31: Long-term Line of Credit, Noncurrent $37.94M.
- 2023-12-31: Long-term Line of Credit, Noncurrent $0.00.
- 2023-09-30: Long-term Line of Credit, Noncurrent $38.80M.
- 2023-06-30: Long-term Line of Credit, Noncurrent $12.71M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2024-03-31 | $37.94M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-09-30 | $38.80M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $12.71M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $12.91M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $12.80M 10-K · filed 2024-04-01 |
| 2022-09-30 | $12.80M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $12.80M 10-Q · filed 2022-08-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |